+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 39 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.

Age: 18Years +All GendersPhase 3
95 locations
R

Actively Recruiting

Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.

Age: 18Years - 80YearsAll GendersPhase 2
107 locations
S

Actively Recruiting

Researchers are evaluating new treatments for follicular lymphoma FL, a type of cancer. This trial studies the combination of a new immunotherapy drug, MK-1045, with rituximab, a targeted therapy, compared to the usual treatment of rituximab combined with chemotherapy. The goal is to assess safety, tolerability, cancer response, and how long participants live without disease progression. Participants receive escalating doses of MK-1045 once weekly for up to about 12 months along with rituximab every 4 weeks for up to 6 months. In a comparison group, participants receive standard chemotherapy options chosen by their doctor plus rituximab for up to 4 to 6 months depending on the regimen. The study includes two parts a dose-finding phase and a randomized phase to compare treatments. During the study, participants undergo regular monitoring for side effects and treatment response over several years. Evaluations include imaging to measure cancer, laboratory tests, and questionnaires about quality of life. The main outcomes measured are adverse events, treatment discontinuation due to side effects, cancer remission rates, progression-free survival, and overall survival. Follow-up lasts up to around 5 years after treatment starts.

Age: 18Years +All GendersPhase 2Phase 3
35 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
E

Actively Recruiting

Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.

Age: 18Years +All GendersPhase 3
182 locations
E

Actively Recruiting

Researchers are evaluating enlicitide decanoate, an oral PCSK9 inhibitor, for treating children and adolescents aged 6 to 17 years with heterozygous familial hypercholesterolemia HeFH who have high levels of low-density lipoprotein cholesterol LDL-C in their blood. The study aims to assess the safety, tolerability, and how the body processes enlicitide, as well as its ability to lower cholesterol compared to a placebo. This is a combined Phase 23 treatment trial sponsored by Merck Sharp & Dohme LLC. Participants receive enlicitide decanoate orally once daily with dosage based on age. The study includes an initial short 2-week treatment period Part A, followed by a 24-week period Part B where participants receive either enlicitide or a placebo. Those completing either part may join an open-label extension, receiving enlicitide daily for up to 3 years. The study uses a randomized, parallel design with quadruple masking. Throughout the study, participants undergo blood tests to measure drug concentration and cholesterol levels, including LDL-C and other lipid markers. Safety is closely monitored by tracking adverse events and treatment discontinuations over approximately 3.5 years. Researchers also assess changes in carotid artery thickness. Visits occur regularly during treatment phases, with long-term follow-up in the extension phase, allowing evaluation of both short- and long-term effects of enlicitide in this pediatric population.

Age: 6Years - 17YearsAll GendersPhase 2Phase 3
47 locations
R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations

1-10 of 39

1